Sickle Cell Treatment Act of 2018 Passed in Congress, Now Awaits President’s Signature
On December 10, 2018, S.2465 – The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018 – was passed by the Congress and now moves forward for the President to sign into law.
“It is amazing what can happen when our collective voices sound together to affect positive change,” said SCDAA President and CEO Beverley Francis-Gibson. “We are grateful for this legislative victory and to all of the individuals living with SCD and their families for their strength and for their efforts to be heard. The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018 marks another step forward in our collective efforts to better understand the prevalence and outcomes of SCD through research and to address the complex needs of the sickle cell community.”
Sickle Cell Disease Association of America, Inc. thanks Senator Tim Scott (R-SC) and Senator Cory Booker (D-NJ) for their leadership and for introducing the bill on February 28, 2018, and we thank the bill’s co-sponsors Senator Doug Jones (D-AL), Senator Bill Cassidy (R-LA), Senator Debbie Stabenow (D-MI), and Senator Elizabeth Warren (D-MA).
SCDAA also thanks Congressman Danny Davis (D-IL), a long-time champion for the sickle cell community; Congressman Michael Burgess (R-TX); and Congressman G.K. Butterfield (D-NC) for supporting this bill in the U.S. House of Representatives. In addition, we are grateful to the members of the Sickle Cell Caucus and to our key partners such as the American Society of Hematology (ASH), Sick Cells, Sickle Cell 101, the SickleCellForum, #BoldLipsforSickleCell and the EveryLife Foundation.